Bristol-Myers Squibb (BMY) announced Friday morning that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in the treatment of lung cancer, based on a review of current data.
from RTT - Before the Bell http://ift.tt/2k7Pvdf
via IFTTT
No comments:
Post a Comment